# EDGAR Filing Document

**Accession Number:** 0001695580
**File Stem:** 0001628280-25-041983
**Filing Date:** 2025-9
**Character Count:** 7479
**Document Hash:** 901668efb3a8805065abfbee0080d01e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-041983.hdr.sgml**: 20250912

**ACCESSION NUMBER**: 0001628280-25-041983

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250801

**FILED AS OF DATE**: 20250912

**DATE AS OF CHANGE**: 20250912

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Krogulski Kenneth
- **CENTRAL INDEX KEY:** 0001695580

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33637
- **FILM NUMBER:** 251310105

**MAIL ADDRESS:**
- **STREET 1:** 1600 WEST END AVE., SUITE 1300
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37203
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CUMBERLAND PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001087294
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 621765329
- **STATE OF INCORPORATION:** TN
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1600 WEST END AVENUE
- **STREET 2:** SUITE 1300
- **CITY:** NASHVILLE,
- **STATE:** TN
- **ZIP:** 37203
- **BUSINESS PHONE:** 615-255-0068

**MAIL ADDRESS:**
- **STREET 1:** 1600 WEST END AVENUE
- **STREET 2:** SUITE 1300
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37203

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Krogulski Kenneth<br><sub>(Last) (First) (Middle)</sub><br>1600 WEST END AVE., SUITE 1300<br><sub>(Street)</sub><br>NASHVILLE, TN 37203<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-08-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CUMBERLAND PHARMACEUTICALS INC [ CPIX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-08-01 |  | P | V | 68<sup>(1)</sup> | A | $3.44 | 288413 | D |  |
| Common Stock | 2025-08-04 |  | P | V | 68<sup>(1)</sup> | A | $4.01 | 288481 | D |  |
| Common Stock | 2025-08-05 |  | P | V | 68<sup>(1)</sup> | A | $3.92 | 288549 | D |  |
| Common Stock | 2025-08-06 |  | P | V | 68<sup>(1)</sup> | A | $3.34 | 288617 | D |  |
| Common Stock | 2025-08-07 |  | P | V | 68<sup>(1)</sup> | A | $3.14 | 288685 | D |  |
| Common Stock | 2025-08-08 |  | P | V | 68<sup>(1)</sup> | A | $3.39 | 288753 | D |  |
| Common Stock | 2025-08-11 |  | P | V | 68<sup>(1)</sup> | A | $2.87 | 288821 | D |  |
| Common Stock | 2025-08-12 |  | P | V | 68<sup>(1)</sup> | A | $2.91 | 288889 | D |  |
| Common Stock | 2025-08-13 |  | P | V | 68<sup>(1)</sup> | A | $2.94 | 288957 | D |  |
| Common Stock | 2025-08-14 |  | P | V | 68<sup>(1)</sup> | A | $2.84 | 289025 | D |  |
| Common Stock | 2025-08-15 |  | P | V | 68<sup>(1)</sup> | A | $3.02 | 289093 | D |  |
| Common Stock | 2025-08-18 |  | P | V | 68<sup>(1)</sup> | A | $3.11 | 289161 | D |  |
| Common Stock | 2025-08-19 |  | P | V | 68<sup>(1)</sup> | A | $3.23 | 289229 | D |  |
| Common Stock | 2025-08-20 |  | P | V | 12<sup>(1)</sup> | A | $3.15 | 289241 | D |  |
| Common Stock | 2025-08-21 |  | P | V | 68<sup>(1)</sup> | A | $3.31 | 289309 | D |  |
| Common Stock | 2025-08-22 |  | P | V | 68<sup>(1)</sup> | A | $3.32 | 289377 | D |  |
| Common Stock | 2025-08-25 |  | P | V | 68<sup>(1)</sup> | A | $3.32 | 289445 | D |  |
| Common Stock | 2025-08-26 |  | P | V | 68<sup>(1)</sup> | A | $3.39 | 289513 | D |  |
| Common Stock | 2025-08-27 |  | P | V | 68<sup>(1)</sup> | A | $3.44 | 289581 | D |  |
| Common Stock | 2025-08-28 |  | P | V | 68<sup>(1)</sup> | A | $3.47 | 289649 | D |  |
| Common Stock | 2025-08-29 |  | P | V | 68<sup>(1)</sup> | A | $3.45 | 289717 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The reported purchase occurred automatically pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 14, 2024.

**Signature:** Kenneth J. Krogulski by /s/ John Hamm as attorney-in-fact  
**Date:** 2025-09-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**